Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	44D0986736	08/11/2022
Name of Provider or Supplier	**Street Address, City, State**	
Pediatric Partners Of Memphis	6063 Mt Moriah Ext Suite 13, Memphis, TN	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory participation in two out of three proficiency testing (PT) events for the red blood cell (RBC), hemoglobin (HGB), white blood cell (WBC), and platelet (PLT) analytes, resulting in the first unsuccessful PT occurrence for the RBC, HGB, WBC, PLT analytes. (Refer to D2130)
D2130	HEMATOLOGY CFR(s): 493.851(f)

	Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a desk review of the Centers for Medicare and Medicaid Services Casper Report 155 (CMS 155) and the laboratory's 2021 and 2022 proficiency testing (PT) records, the laboratory failed to maintain satisfactory performance for the red blood cell count (RBC), hemoglobin (HGB), white blood cell count (WBC), and platelet count (PLT) analytes in two out of three PT events, resulting in the first unsuccessful PT occurrence for the RBC, HGB, WBC, and PLT analytes. The findings include: 1. Review of the CMS 155 revealed the following unsatisfactory PT scores: a. 2021 event three: 60% for RBC, HGB, WBC, PLT b. 2022 event two: 0% for RBC, HGB, WBC, PLT 2. Review of the laboratory's PT evaluation report revealed the following: a. 2021 event one: unacceptable scores for sample numbers HD-14 and HD-15 for the RBC, HGB, WBC, and PLT analytes, resulting in a score of 60% for each analyte. b. 2022 event two: no scores for the RBC, HGB, WBC, and PLT analytes for "No Results Received", resulting in an overall score of 0% for each analyte and the first unsuccessful PT occurrence for the RBC, HGB, WBC, and PLT analytes.